Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality Improvement.

ABSTRACT:

Importance

Diverse racial and ethnic representation in clinical trials has been limited, not representative of the US population, and the subject of pending US Food and Drug Administration guidance. Psoriasis presentation and disease burden can vary by skin pigmentation, race and ethnicity, and socioeconomic differences. Overall, there are limited primary data on clinical response, genetics, and quality of life in populations with psoriasis and skin of color (SoC). The Varying Skin Tones in Body and Scalp Psoriasis: Guselkumab Efficacy and Safety trial (VISIBLE) is underway and uses strategies aimed at addressing this persistent gap.

Objective

To assess the innovative strategies used in the VISIBLE trial to recruit and retain diverse participants in a randomized clinical tri

SUBMITTER: Alexis A 

PROVIDER: S-EPMC11923717 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature